anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for preparing and screening alkaloid and anti-inflammation active ingredients in dactylicapnos scandens. The method comprises the following steps: carrying out ethanol reflux extraction on a dactylicapnos scandens medicinal material, mixing extracting liquid, reclaiming ethanol in reduced pressure, and concentrating medicinal liquid; carrying out column chromatography on the concentrated liquid; eluting with chloroform, chloroform-methanol in a ratio of 1:1 and methanol-water in a ratio of 1:1 sequentially, collecting eluent, concentrating at reduced pressure, freezing and drying to respectively obtain a chloroform component (CHCl3 Fr.), a chloroform-methanol component (CHCl3-MeOH Fr.) and a methanol-water component (MeOH-H2O Fr.); and mixing the chloroform component and the chloroform-methanol component to obtain a dactylicapnos scandens alkaloid component, and screening the optimized anti-inflammatory active component (CHCl3-MeOH Fr.). The alkaloid and anti-inflammation active ingredients prepared and screened by adopting the method can be applied to treatment of inflammatory diseases in a safe concentration range, and can provide basis to deep development of the dactylicapnos scandens.
Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
PURPOSE: To provide such an animal feed compsn. comprising a specified tetracycline and an animal feed that can be used to safely treat for diseases of animals caused by excess collagen growth, that promotes increase in the body weight of an animal and that is useful for cow or the like without causing cause excess growth of organisms having resistance. CONSTITUTION: This animal feed compsn. consists of (A) a tetracycline described below and (B) an animal feed. The tetracycline (A) does not substantially have anitimicrobial activity and has anticollagenase activity or anticolalgen destroying enzyme activity, and is selected from decymethylaminotetracycline, nitrile analogue of tetracycline, 6α-benzylthiometylenetetracycline, mono-N-alkylamide tetracycline, 6-fluorodimethyltetracycline and 11α-chlorotetracycline. The tetracycline is preferably compounded by 10 to 200 g per 1 ton of the feed. The tetracycline is preferably fed by 0.1 to 1.0 mg per one pound per one day for a young cow as age of up 12 weeks.
Bermudagrass (Cynodon dactylon) is a globally distributed, extensively used warm-season turf and forage grass with high tolerance to salinity and drought stress in alkaline environments. However, the origin of the species and genetic mechanisms for salinity tolerance in the species are basically unknown. Accordingly, we set out to study evolution divergence events in the Cynodon genome and to identify genes for salinity tolerance. We developed a 604.0 Mb chromosome-level polyploid genome sequence for bermudagrass 'A12359' (n = 18). The C. dactylon genome comprises 2 complete sets of homoeologous chromosomes, each with approximately 30 000 genes, and most genes are conserved as syntenic pairs. Phylogenetic study showed that the initial Cynodon species diverged from Oropetium thomaeum approximately 19.7-25.4 million years ago (Mya), the A and B subgenomes of C. dactylon diverged approximately 6.3-9.1 Mya, and the bermudagrass polyploidization event occurred 1.5 Mya on the African continent. Moreover, we identified 82 candidate genes associated with seven agronomic traits using a genome-wide association study, and three single-nucleotide polymorphisms were strongly associated with three salt resistance genes: RAP2-2, CNG channels, and F14D7.1. These genes may be associated with enhanced bermudagrass salt tolerance. These bermudagrass genomic resources, when integrated, may provide fundamental insights into evolution of diploid and tetraploid genomes and enhance the efficacy of comparative genomics in studying salt tolerance in Cynodon.
Levetiracetam USP is an antiepileptic drug available as beige colored tablets in 1000 mg strength for oral administration.

The chemical name of levetiracetam USP, a single enantiomer, is (-)-(S)-a-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam USP is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula:

Levetiracetam USP is a white to off-white crystalline powder. It is very soluble in water, freely soluble in methanol, chloroform and ethanol. Soluble in acetonitrile and practically insoluble in n-hexane.

Levetiracetam tablets USP contain the labeled amount of levetiracetam USP. Inactive ingredients: magnesium stearate, povidone, and film coating agent contains hypromellose 3cp, hypromellose 6cp, iron oxide yellow, iron oxide red, polyethylene glycol 400, polysorbate 80 and titanium dioxide.
AD is a chronic inflammatory skin disease characterized by frequent viral skin infections. Recent studies have found that components in the skin of people with AD may block AMP expression. AMPs are responsible for preventing infection from viruses. The purpose of this study is to examine smallpox virus replication and AMP expression in the skin of patients with AD as well as identify other antiviral molecules involved in immune response. These findings will be compared with those of people with psoriasis or asthma, or healthy individuals. This study will consist of one study visit at which skin and blood samples will be taken.
BACKGROUND AND OBJECTIVE: Active surveillance (AS) of prostate cancer (PCa) involves regular monitoring for disease progression. The aim is to avoid unnecessary treatment while ensuring appropriate and timely treatment for those whose disease progresses. AS has emerged as the standard of care for low-grade (Gleason grade 1, GG 1) PCa. Opponents are concerned that initial undersampling and delay of definitive management for patients with GG 2 disease may lead to adverse outcomes. We sought to determine whether the timing for definitive management of GG 2 PCa, either upfront or after initial AS, affects recurrence outcomes after radical prostatectomy (RP).
METHODS: Participants were diagnosed with cT1-2N0/xM0/x, prostate-specific antigen (PSA) <20 ng/ml, and GG 1-2 PCa between 2000 and 2020 and underwent immediate RP for GG 2 or AS followed by delayed RP on upgrading to GG 2. The outcome was recurrence-free survival (RFS) after surgery, with recurrence defined as either biochemical failure (2 PSA measurements ≥0.2 ng/ml) or a second treatment. Multivariable Cox proportional-hazards regression models were used to calculate associations between the timing for definitive RP and the risk of recurrence, adjusted for age at diagnosis, percentage of positive biopsy cores (PPC), PSA density, PSA before RP, year of diagnosis, surgical margins, genomic risk score, and prostate MRI findings.
KEY FINDINGS: Of the 1259 men who met the inclusion criteria, 979 underwent immediate RP after diagnosis of GG 2, 190 underwent RP within 12 mo of upgrading to GG 2 on AS, and 90 men underwent RP >12 mo after upgrading to GG 2. The 5-yr RFS rates were 81% for the immediate RP group, 80% for the delayed RP ≤12 mo, and 70% for the delayed RP >12 mo group (univariate log-rank p = 0.03). Cox multivariable regression demonstrated no difference in RFS outcomes between immediate RP for GG 2 disease and delayed RP after upgrading on AS. PPC (hazard ratio [HR] per 10% increment 1.08, 95% confidence interval [CI] 1.02-1.15; p = 0.01) and PSA before RP (HR 1.06, 95% CI 1.03-1.09; p < 0.01) were significantly associated with the risk of recurrence.
CONCLUSIONS AND CLINICAL IMPLICATIONS: PPC and PSA before RP, but not the timing of definitive surgery after upgrade to GG 2, were associated with the risk of PCa recurrence after RP on multivariable analysis. These findings support the safety of AS and delayed definitive therapy for a subset of patients with GG 2 disease.
PATIENT SUMMARY: In a large group of 1259 patients with low-grade prostate cancer, we found that delaying surgical treatment after an initial period of active surveillance resulted in no differences in prostate cancer recurrence. Our results support the safety of active surveillance for low-grade prostate cancer.
In adolescents, anorexia nervosa severely affects physical, emotional, and social development. Despite the seriousness and prevalence of adolescent anorexia nervosa, few studies have focused on the effectiveness of various types of psychotherapy treatment. Family-based therapy may be an effective approach to treating adolescent anorexia nervosa. This study will compare specific family therapy (FT), standard family systems therapy (FS), and standard individual psychotherapy (IT) to determine which is most effective in treating adolescent anorexia nervosa. The study also aims to determine potential predictors and moderators of outcomes, as well as the cost-benefit ratio of each treatment.

Participants in this open-label study will be randomly assigned to one of three treatment groups. Group 1 will receive FT, Group 2 will receive FS, and Group 3 will receive IT. All participants will receive a total of 24 hours of their assigned therapy over a period of 12 months. Study visits will occur at baseline, immediately post-intervention, and again six months and one year post-intervention. Weight change will be assessed, as well as changes in concerns about weight and shape. The cost-benefit ratio of the treatments will also be evaluated.
Patients diagnosed pathologically as cervical cancer (squamous carcinoma, adenocarcinoma or adenosquamous carcinoma) with stage of FIGO IB3 and IIA2 to IVB will be included in this study according to the prescribed criteria in the protocal. Classical radiochemotherapy will be conducted by clinical routine method. Radiation will be given by external beam radiation of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Apart from that, hydrochloride anlotinib, a multiple targets anti-angiogenesis kinase approved by CFDA, will be orally taken daily at a dose of 12mg for 14 days aiming to improve tumor response. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation. Once the treatment is finished, patients will be examination for tumor evaluation and toxicity monitor every 3 months for the first 2 years and then every half years for the third year unless progression or death. During those period, patient characteristics, image data, tumor tissue, blood, urine, stool and microbial sample of tumor micro environment will be collected and analysis by multi-omics and bioinformatic technology. A total of 53 patients will be included and this study will be conducted in the department of radiation and clinical oncology in Zhongnan Hospital of Wuhan University.
The present invention is characterized by the preparation of semicarbazone and/or thiosemicarbazone formulations with cyclodextrins and their derivatives and products obtained by this process. The present invention is characterized by obtaining inclusion compounds of semicarbazone and/or thiosemicarbazones with cyclodextrins and their derivatives, which were tested in experimental epilepsy models and allowed the reduction of the anticonvulsant dose from 100mg/kg. This means an improvement in the bioavailability of the compounds in biological systems. These results obtained in animal models make semicarbazones and/or thiosemicarbazones included in cyclodextrins and their derivatives new anticonvulsant candidates. The present invention is also characterized by the improved efficacy of semicarbazones and/or thiosemicarbazones included in cyclodextrins and their derivatives in comparison to free components. In addition the present invention is also characterized by the pain killer effect of semicarbazones and thiosemicarbazones. The present invention is also characterized by a lowering of the dose necessary for the pain killer effect of semicarbazones and thiosemicarbazones upon inclusion into cyclodextrins.
PURPOSE:To obtain the titled cosmetic having slightly caking surface, excellent dispersibility of pigment, a moist feeling in use and excellent impact resistance, moldable into any shape, containing water swelling clay minerals having actions as a surface active agent, powder and an oil component in a specific ratio. CONSTITUTION:The titled solid powder cosmetic containing 60-99wt.% powder such as talc, kaolin, nylon powder, etc., 0.5-30wt.% oil component such as squalane, liquid paraffin, vaseline, etc., and 0.05-5wt.% water swelling clay minerals such as magnesium aluminum silicate, etc. In production, first the powder is blended with the water swelling clay minerals by Henschel mixer, sprayed with the oil component, blended and powdered by a pulverizer. Then 100pts.wt. of the composition is mixed with 10-100pts.wt. water or another solvent, put into a old of an arbitrary shape under pressure and dried at 40-90 deg.C to give a solid powder cosmetic of arbitrary shape.
Pathogenic germline mutations in the P-type copper-transporting ATPase (ATP7B) gene cause Wilson's disease (WD), a hereditary disorder characterized by disrupted copper metabolism. The Arg778Leu (R778L) mutation in exon 8 is prevalent among individuals with WD in East Asia and is associated with more severe phenotypes. In this study, we generated a WD mouse model harboring R778L mutation (R778L mice) using CRISPR/Cas9. R778L mice exhibit a range of pathological characteristics resembling those of patients with WD and the same point mutations, including aberrant copper metabolism, pathological cellular injury, inflammation, and severe hepatic fibrosis. At 3-5 months of age, these mice started to display neurological deficits in motor coordination and cognitive dysfunction, accompanied by increased expression of inflammatory cytokines in the central nervous system. Microglia in the striatum and cortex exhibit significant activation, shorter processes, and decreased branch points. However, the Cu2+ levels in the brain tissue of R778L mice did not differ significantly from those of wild-type mice. Notably, inhibition of hepatic inflammation with PJ34 or siNfkb markedly alleviated the deficiencies in cognitive performance and improved locomotor activity in R778L mice. Thus, this study establishes a novel murine model to investigate the pathophysiology of WD, highlights the liver-brain crosstalk responsible for neurological manifestations in individuals with WD caused by the R778L point mutation, and demonstrates the potential of modulating liver inflammation as a therapeutic strategy for alleviating the neurological manifestations of WD.
Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of "seeing leaflets, accumulating points, and redeeming prizes" is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a " Stool diary record sheet " every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw.
PROBLEM TO BE SOLVED: To obtain the subject tablet that can increase the content of the medicine as high as possible, can be readily tabletted, and enable sustained release of the medicine by allowing the tablet to contains granulated substance prepared by coating bulk medicine particles with a binder. SOLUTION: This medicine contains granules prepared from bulk medicine particles. These granules are obtained by coating the bulk medicine particles with a binder and have an average particle size of 25-200μm, optimally 30-60μm. The amount of the binder added is 25-75wt.% based on the weight of the bulk medicine particles, the binder layer coated can contain a plasticizer and the amount of the plasticizer is 5-15wt.% based on the binder. The resultant granulated product is tabletted, preferably in the presence of a fluidizing agent, with a compression pressure that the tablet hardness reaches 4-10kg. Thus, even when the physical properties of the bulk medicine are different in the production process, the handling operations can be done in the same manner at the tabletting step and the tabletted medicine can have a suitable sustained release properties.
The invention discloses a viburnum sargenti Viburnum    congestum  Red.) extract, cosmetics containing the same as active ingredient, and application thereof. Belongs to the technical field of cosmetics and medicines. The viburnum sargentii extract is a 95% ethanol extract of the branches and leaves of the viburnum sargentii, the extract is dispersed in water, ethyl acetate and water are extracted in two phases by volume to obtain an ethyl acetate part and a water layer part, and the extract, the ethyl acetate part and the water layer part have good DPPH free radical scavenging capability and tyrosinase activity inhibiting effect. In the aspect of skin care, the viburnum sargentii extract, the ethyl acetate part and the water layer part have good antioxidant capacity and melanin removing capacity, namely have good skin cosmetic activity application potential of resisting wrinkle, preventing sunburn, whitening or removing melanin (spots). The invention effectively utilizes the folk medicinal plant-viburnum sargenti of China to obtain the product with obvious lifeThe extract can be used for preparing good antioxidant and tyrosinase activity inhibitor, and is a good natural plant cosmetic raw material.
The present invention provides methods and apparatuses for use in providing rapid, selective and effective targeted delivery of beneficial substances into hair follicles by use of a vibrator (1) for vibrating a chamber with a substance (2) to be delivered to the skin (3). The invention relies on the use of a vibrational method of delivery of substances of different size from small molecules up to particles compatible with the diameter of hair strand into the hair bulb. The skin is subjected to the vibration of about 1 Hz to about 100 Hz frequency, and 0.1 mm to about 10 mm amplitude, an amount which is sufficien t to cause mechanical shifts in different directions of skin structure without damage. This results in follicle effective uptake of the tested substances such as carbon particles of different size as well as melanin. The methods and apparatuses of the present invention are particularly useful in conjunction with photosensitizing agents and electromagnetic irradiation. Such a combination is used to target the delive ry ofagent within hair follicles and then subsequently activate the agent. >
PURPOSE: Intraoperative fascial traction (IFT) for the treatment of large ventral hernias and loss of domain (LOD) hernias is a promising tool in abdominal wall surgery. However, little is known about the extent of gain in myofascial advancement especially for the anterior rectus sheath. We, therefore, used a cadaveric model to determine the medialization during IFT.
METHODS: 4 fresh frozen specimens were used. Retromuscular preparation was carried out followed by IFT with diagonal vertical traction for 30 min. Medial advancement of the anterior rectus sheath was measured after 15 and 30 min as well as traction forces.
RESULTS: Total medialization for anterior rectus sheath after 30 min of IFT was 10.5 cm (mean). The mean traction force was 16.28 kg. Total medialization was significantly higher during the first 15 min of vertical fascial traction (p < 0.05).
CONCLUSIONS: IFT provides significant medialization for the anterior rectus sheath in the cadaveric model. The findings align with results from a retrospective case study. Therefore, we see IFT as a beneficial tool in abdominal wall surgery.
An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap extends from an end cap distal end to an end cap inner end. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. The air channel is non-parallel with the longitudinal axis.
Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
The invention discloses a porcine actinobacillus pleuropeumoniae ClpP protease gene-deleted strain containing no resistance marker, and a construction method thereof. The invention belongs to the technical field of bacteria genetic engineering. According to the invention, a recombinant strain APPdeltaclpP of actinobacillus pleuropeumoniae is a strain obtained through coding gene deactivation upon ClpP protease in actinobacillus pleuropeumoniae with an oriented homologous recombination technology, and the expression of the ClpP protease is damaged. With the technology provided by the invention, the virulence of the mutant strain is lower than a parent strain, and the mutant strain is safe to animals. Therefore, an important basis is provided for the modification upon porcine contagious pleuropneumonia vaccines and the development of corresponding differential diagnosis reagents. The strain and the method provided by the invention have important significances in promoting the eradication and purification of porcine contagious pleuropneumonia all around the world.
All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
A new class of mass label polymers is provided which include enriched metal isotopes, such as zirconium and hafnium mass labels. These new mass tags differ in chemistry from lanthanide mass tags and open up new mass channels that can be used for mass cytometry. These polymers may be used for mass cytometry, therapeutic delivery of radioisotopes, or screening of therapeutic isotopes. Aspects include kits, methods of making polymers, isotopic compositions, or both, and methods of using the same. The kit may include a polymer. The polymer may include pendant groups that chelate rich isotopes, such as zirconium and/or hafnium. The kit may include an isotopic composition comprising an enriched isotope of zirconium or hafnium. The polymer may be conjugated to a bioactive material. Aspects may also include preparing a kit. Aspects include the use of the kit, such as for mass cytometry.